Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Fig. 1

Number of circulating tumor cells (CTCs) at stages 0–I, II, and III. a Number of CTCs in healthy individuals and melanoma patients at stages 0–I, II, and III. CTCs were counted using blood samples collected before surgical resection of the primary tumor and sentinel node biopsy. b, c Pathologic features of stage I primary melanoma. Atypical melanocytes invaded the dermis in a nodular and diffuse manner. Tumor thicknesses were 0.6 (b) and 0.8 mm (c). Clark levels were III (b) and IV (c) (× 100, hematoxylin/eosin staining)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us